First quarter net revenues were $219 million. Income from operations was $26.8 million. Operating margin of 12.2%. Diluted earnings per share increased by 2 cent on last year to 37c. Net new business wins in the quarter of $265m, representing a book-to-bill ratio of 1.2. Dublin, Ireland, April 27, 2010 – ICON (NASDAQ: ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the first quarter ended March 31, 2010. Net revenues for the quart
ICON and Tigermed Consulting, a leader in the provision of clinical drug development services in China, today announced that they have signed an alliance agreement. Through this agreement, ICON and Tigermed will collaborate to offer pharmaceutical and biotechnology clients better access to Chinese patients, utilising the global reach and experience of the ICON organisation, complemented by Tigermed’s in depth knowledge of the Chinese drug development landscape and geographic coverage in China.
ICON has expanded its footprint in Asia-Pacific with the opening of an office in Manila, Philippines. This announcement follows the recent expansion of ICON’s operations in Seoul, Korea and ICON Central Laboratories’ move to a larger laboratory facility in Singapore.
ICON reports Full-Year 2009 EPS growth of 18% and announces Revenue and EPS Guidance for 2010
Mr. Bob Scott-Edwards has retired from the position of President, ICON Central Laboratories. Mr. Tom O’Leary, previously Senior Vice President and Global Head of Data Management, ICON Clinical Research, has succeeded Mr. Scott-Edwards.
ICON has expanded its European Central Laboratory in Dublin. The newly-designed 41,000 sq ft (3,800m²) facility, which is three times the size of the previous laboratory, provides centralised testing and site support services to clinical investigators in over 70 countries throughout Europe, Middle East and Africa.
The unit is the first deliverable from a collaborative agreement between ICON and the Central Manchester University Hospitals Foundation (CMFT) to develop purpose-built translational medicine facilities on the newly-developed Manchester Royal Infirmary (MRI) campus.
ICON has signed an extension to its strategic agreement with Eli Lilly and Company to manage the company’s clinical data management outside the US. This extension means that ICON will now also manage Lilly’s needs in Japan in addition to those in Europe, Canada, Latin America, Australia and Asia.
a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for its third quarter ended September 30, 2009.